Compare FCT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCT | BNR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.5M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | FCT | BNR |
|---|---|---|
| Price | $9.44 | $16.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.4K | 30.5K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 11.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.25 | $2.18 |
| 52 Week High | $10.29 | $41.72 |
| Indicator | FCT | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 36.16 |
| Support Level | $9.41 | $15.52 |
| Resistance Level | $10.06 | $23.42 |
| Average True Range (ATR) | 0.08 | 1.28 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 9.46 | 7.97 |
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.